Sign in to fuzzto save your conversations, follow your research and come back anytime.
Cohance Lifesciences
SectorHealthcare
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Company insights, generated from the most recent coverage.
Management expects double-digit Specialty Chemicals growth from FY28, contingent on customer qualification and regulatory timelines — a two-year wait, not a near-term offset to Chinese generic price pressure.
Crisil awarded a voluntary 'Strong' ESG rating on 6 Oct — a low-cost credibility signal that helps with institutional screens and customer qualification audits for a CDMO chasing pharma clients.
Traders appear to be positioning ahead of Q2 FY27 results on the view that Q1 was the trough — trading window closed since 1 Oct and the board meeting date is still unannounced, so the move is running ahead of confirmation.
